ライフサイエンスコーパス: monoamine oxidase B

1 rmed with 1-PCPA and mammalian mitochondrial monoamine oxidase B.

2 d selective inhibitor of brain mitochondrial monoamine oxidase B.

3 s formed during the bioactivation of MPTP by monoamine oxidase B.

4 g agent, flecainide, which has no recognized monoamine oxidase B activity, and which has previously b

5 example of a biorelevant synthetic model for monoamine oxidase B activity.

6 amine N-methyl transferase) and disposition (monoamine oxidase B and catechol-O-methyl transferase) o

7 ned most (50-60%) of marker enzyme activity, monoamine oxidase-B and porin proteins, but only about 2

8 ic groups that exist in catalytically active monoamine oxidase B are physically distinct.

9 rkinson's disease based on its inhibition of monoamine oxidase B, but the drug is also a potent state

10 We performed a genomewide scan of monoamine oxidase B for the Collaborative Study on the G

11 trate for the flavin-dependent mitochondrial monoamine oxidase B from bovine liver.

12 a targeting enzyme to disrupt the endogenous monoamine oxidase B gene in human cells.

13 onoamine oxidases with slight preference for monoamine oxidase B in both species.

14 SKF-38393 had no effects either on total or monoamine oxidase B in the striatum.

15 We report the effects of the addition of a monoamine oxidase B inhibitor, rasagiline, to antidepres

16 est placebo-controlled clinical trial of the monoamine oxidase B inhibitor, rasagiline, we examined h

17 2D6 inhibitor, quinidine, and also partly by monoamine oxidase B inhibitors deprenyl and pargyline.

18 Monoamine oxidase B inhibitors result in a mild improvem

19 his, a number of highly potent and selective monoamine oxidase B inhibitors were identified.

20 dowed with potent, selective, and reversible monoamine oxidase B inhibitory activity is a clinically

21 Also, we demonstrate that monoamine oxidase B is an ERRalpha target gene whose exp

22 -deuterium-L-deprenyl ((11)C-DED) to measure monoamine oxidase B located in astrocytes.

23 Monoamine oxidase B (MAO B) catalyzes the oxidative deam

24 direct and continuous fluorometric assay for monoamine oxidase B (MAO B) has been developed.

25 The monotopic membrane protein monoamine oxidase B (MAO B) is an important drug target

26 Monoamine oxidase B (MAO B) is an integral protein of th

27 al reversible inhibitors selective for human monoamine oxidase B (MAO B) that do not inhibit MAO A ha

28 ture and subunit composition of bovine liver monoamine oxidase B (MAO B) was investigated using size-

29 (AD), i.e., acetylcholinesterase (AChE) and monoamine oxidase B (MAO B), a series of multitarget lig

30 time-dependent, irreversible inactivators of monoamine oxidase B (MAO B).

31 smokers show a 40% decrease in the level of monoamine oxidase B (MAO B; EC 1.4.3.4) relative to non-

32 A set of drugs was further studied in monoamine oxidase B (MAO-B) and cyclooxygenase-1 (COX-1)

33 mine and compare how two monotopic proteins, monoamine oxidase B (MAO-B) and cyclooxygenase-2 (COX-2)

34 Age-related increases in brain monoamine oxidase B (MAO-B) and its ability to produce r

35 l) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10

36 enosine receptors (A2AARs) and inhibition of monoamine oxidase B (MAO-B) in the brain are considered

37 mined the effects of GM1 ganglioside and the monoamine oxidase B (MAO-B) inhibitor L-deprenyl, alone

38 llular model of Parkinson's disease in which monoamine oxidase B (MAO-B) is overexpressed and which e

39 evious finding that smokers have lower brain monoamine oxidase B (MAO-B) levels than comparison nonsm

40 The monoamine oxidase B (MAO-B) substrate properties and dis

41 Monoamine oxidase B (MAO-B) was recently identified as a

42 e, competitive, and reversible inhibitors of monoamine oxidase B (MAO-B).

43 or (NMDAR), acetylcholinesterase (AChE), and monoamine oxidase B (MAO-B).

44 nt inhibitor of the flavin-containing enzyme monoamine oxidase B (MAO-B).

45 Monoamine oxidase-B (MAO-B) is a key enzyme in the catab

46 MPTP is converted by monoamine oxidase-B (MAO-B) to its neurotoxic metabolite

47 diographically in conscious mice without the monoamine oxidase B (MAOB) gene (KO, n=11) and the corre

48 was found to suppress the gene expression of monoamine oxidase B (MAOB) in the brain of wild-type but

49 brane domains from the mitochondrial protein monoamine oxidase B (MaoB) or the endoplasmic reticulum

50 tural comparisons with human metabolites and monoamine oxidase B (MAOB) was identified as the putativ

51 oduce the inhibitory gliotransmitter GABA by monoamine oxidase-B (Maob) and abnormally release GABA t

52 ent complex I inhibitor and the two electron monoamine oxidase B oxidation product of MPTP.

53 Monoamine oxidase B, present in the mitochondrial outer

54 ate, decreased benzodiazepine, and increased monoamine oxidase B receptor binding have been reported.

55 nction and these include redox-related genes monoamine oxidase B, ryanodine receptor 2, and glutathio